GW&K Investment Management LLC Buys 323,674 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GW&K Investment Management LLC grew its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 18.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,123,488 shares of the medical device company’s stock after buying an additional 323,674 shares during the quarter. GW&K Investment Management LLC owned approximately 3.23% of Tandem Diabetes Care worth $76,488,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TNDM. Baillie Gifford & Co. grew its stake in shares of Tandem Diabetes Care by 235.7% during the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after acquiring an additional 523,843 shares during the period. Bellevue Group AG lifted its holdings in Tandem Diabetes Care by 19.9% during the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after purchasing an additional 307,624 shares in the last quarter. Stephens Investment Management Group LLC boosted its position in shares of Tandem Diabetes Care by 22.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock worth $56,040,000 after purchasing an additional 281,327 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Tandem Diabetes Care by 397.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock worth $11,121,000 after purchasing an additional 240,966 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Tandem Diabetes Care in the third quarter worth $10,208,000.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a research note on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday. Barclays increased their target price on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Citigroup lowered their price target on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Robert W. Baird cut their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.38.

Tandem Diabetes Care Trading Down 35.2 %

TNDM opened at $21.75 on Friday. The stock has a 50-day moving average of $35.45 and a 200 day moving average of $36.62. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12 month low of $21.43 and a 12 month high of $53.69. The firm has a market cap of $1.43 billion, a P/E ratio of -11.27 and a beta of 1.32.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.